头孢呋辛临床药动学的研究进展(英文)  

Progress in the clinical pharmacokinetics of cefuroxime

作　　者：赵龙山[1] 李清[1] 何博赛[1] 王洁[1] 陈晓辉[1] 毕开顺[1] 

机构地区：[1]沈阳药科大学药学院,沈阳110016

出　　处：《中国抗生素杂志》2012年第10期721-727,共7页Chinese Journal of Antibiotics

摘　　要：目的综述头孢呋辛钠和头孢呋辛酯的临床药动学的研究进展。方法查阅国内外文献并进行分析归纳和总结。结果头孢呋辛在组织和体液中分布广泛,消除快,体内药动学行为符合二室开放模型,头孢呋辛酯水解后以头孢呋辛的形式起作用,饮食影响头孢呋辛酯的生物利用度,在特殊人群中用药量需酌情减量,未见性别差异。结论作为二代头孢类药物代表的头孢呋辛,已入选国家基本药物目录,但仍然需要检测患者血药浓度,避免抗生素滥用,实现个体化给药,达到临床的安全、合理、有效用药。Objective To summarize the progress in the clinical pharmacokinetics of cefuroxime sodium and cefuroxime axile. Methods The literatures at home and abroad were consulted, analyzed and concluded. Results Cefuroxime is widely distributed in tissues and body fluids, and eliminated rapidly, with the pharmacokinetic profile in body best fitted by two-compartment open model, while cefuroxime axile is hydrolysed into cefuroxime which is in action. Food can effect the bioavailability of cefuroxime axile, and more attention should be paid for the special population using lower dosage. No gender differences were found for both formulations. Conclusions As the representation of the second-generation cephalosporins, cefuroxime has been listed in the Catalogue of Basic Medicines of the State, however, therapeutical drug monitoring of patients for cefuroxime should still be taken into consideration, so as to avoid the abuse of antibiotics, achieve individualized drug administration, and finally to come to be safe, reasonable and effective drug use in clinic.

关 键 词：头孢呋辛 头孢呋辛钠 头孢呋辛酯 药动学 

分 类 号：R978.11[医药卫生—药品]